Skip to content

Author

Junhong Han

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Aug 2026

Histone modifications: mechanisms, metabolic regulation and therapeutic targeting in cancer

Histone post-translational modifications are central regulators of chromatin organization and genome function, acting independently of alterations in DNA sequence. This review comprehensively summarizes the multifaceted roles of major histone modifications including acetylation, methylation, ubiquitination, phosphorylation and emerging metabolism-linked acylations in governing critical DNA-templated processes such as replication, transcription, and the DNA damage response. We further discuss the concept of the nuclear metabolic microenvironment, in which local metabolite availability and enzyme activity directly influence the deposition of histone acylation marks and thereby connect metabolic state to chromatin regulation. We also examine how dysregulation of these pathways promotes tumor initiation and progression, facilitates immune evasion, and drives therapeutic resistance. On this basis, we evaluate current therapeutic strategies targeting histone-modifying machinery in cancer, including approved epigenetic drugs, agents in clinical development, biomarker-guided applications, resistance mechanisms, and combination approaches. We further distinguish direct pharmacological targeting of histone writers, erasers, and readers separately from indirect interventions against upstream kinases, metabolic pathways, or organelle-level metabolic remodeling. Together, these observations highlight the biological and translational importance of histone modifications in cancer and support continued development of mechanism-informed and biomarker-guided epigenetic therapies in precision oncology.

Lingli Wang, Shi-Ying Li, Xiaoyan Hu et al. · 0 citations
Open access Jul 2026

Targeting HASPIN-mediated H3T3 phosphorylation disrupts an epigenetic-kinesin axis to suppress colorectal cancer mitotic progression.

Chemoresistance remains a major barrier in colorectal cancer (CRC) therapy. Through epigenetic compound screening in patient-derived organoids (PDOs), we identified CX6258.HCl as a potent growth inhibitor. Treatment with CX6258.HCl significantly inhibited cell mitosis and induced apoptosis in CRC cell lines. Mechanistically, CX6258.HCl binds the D687 residue within HASPIN's kinase domain, suppressing H3T3 phosphorylation (H3T3ph). This triggers an epigenetic cascade: loss of H3T3ph upregulates demethylase KDM5B pre-mRNA, depleting H3K4me3 at promoters of Kinesin family member (KIFC1/KIF10/KIF14). Consequently, microtubule dynamics are disrupted, leading to mitotic arrest. Target specificity was validated genetically via HASPIN-D687A mutation. In vivo, CX6258.HCl suppressed CRC xenograft growth and further enhanced 5-FU-mediated tumor suppression without obvious histological injury in major organs. Clinically, elevated H3T3ph levels in human CRC tissues were associated with Ki67-positive proliferative tumor regions, suggesting that H3T3ph may represent a proliferation-associated marker in CRC. Together, our findings identify the HASPIN/H3T3ph-KDM5B-H3K4me3-KIF axis as a targetable antimitotic pathway and support therapeutic inhibition of HASPIN/H3T3ph as a potential strategy for CRC.

Tong Wu, Yaguang Zhang, Sicheng Liu et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.